Safety and dose-ranging study of the effects of SCH 527123 in subjects with moderate to severe COPD.

Trial Profile

Safety and dose-ranging study of the effects of SCH 527123 in subjects with moderate to severe COPD.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Apr 2017

At a glance

  • Drugs Navarixin (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 16 Sep 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 12 Jul 2011 New source identified and integrated (European Clinical Trials Database; EudraCT2005-004287-23).
    • 22 Sep 2010 Results presented at the 20th Annual Congress of the European Respiratory Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top